Lilly’s ramucirumab fails to crack phase 3 gastric cancer trial

Lilly gastric cancer drug Cyramza (ramucirumab) did meet the primary endpoint of a phase 3 trial RAINFALL but could not improve overall survival of patients.

Lilly’s ramucirumab fails to crack phase 3 gastric cancer trial

Eli Lilly and Company, which is better known as Lilly, says that a late-stage trial of Cyramza (ramucirumab) for the treatment of a form of gastric cancer met its primary goal of stopping the disease from advancing, but failed in improving overall survival. An antiangiogenic therapy, ramucirumab in combination with cisplatin and capecitabine or 5-FU […]

Abemaciclib FDA approval : Lilly breast cancer drug gets regulatory nod

Eli Lilly and Company (Lilly) has bagged the abemaciclib FDA approval to treat advanced breast cancer in patients whose breast cancer had progressed after taking therapy that changed their hormones (endocrine therapy).

Abemaciclib FDA approval : Lilly breast cancer drug gets regulatory nod

Abemaciclib FDA approval : Eli Lilly and Company (Lilly) has secured the US FDA approval for Verzenio (abemaciclib) to treat metastatic breast cancer in patients whose disease had progressed after a prior treatment. Abemaciclib FDA Approval The breast cancer drug approval is for patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 […]

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival (PFS) in a phase 3 breast cancer trial. The combination of Lilly breast cancer drug abemaciclib with fulvestrant was proved to be more effective than the fulvestrant plus placebo combination […]